Table 4 Group differences at 12-months follow-up
From: Effects of weekly pain monitoring on back pain outcomes: a non-randomised controlled study
Continuous outcomes | SMS group versus control group Main analysis | SMS group responding > 26 weeks versus control group Sensitivity analysis | ||
|---|---|---|---|---|
Crude β (95% CI) | Adjusted β (95% CI) | Crude β (95% CI) | Adjusted β (95% CI) | |
LBP at 12 months follow-up, NRS (0–10); mean (SD) | − 0.42 (− 0.65; − 0.19) | − 0.40 (− 0.62; − 0.19) | − 0.48 (− 0.73; − 0.24) | − 0.44 (− 0.68; − 0.21) |
Activity limitation, RMDQ (0–100) | 1.12 (− 1.34; 3.58) | 1.51 (− 0.83; 3.85) | 0.88 (− 1.68; 3.45) | 1.30 (− 1.12; 3.73) |
Ability to control pain, NRS (0–10) | − 0.05 (− 0.28; 0.19) | − 0.08 (− 0.31; 0.15) | − 0.10 (− 0.36; 0.15) | − 0.12 (− 0.37; 0.13) |
Binary outcomes | Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|---|
Pain > 3 | 0.71 (0.58; 0.88) | 0.70 (0.56; 0.88) | 0.66 (0.53; 0.83) | 0.65 (0.50; 0.83) |
Non-improvement of activity limitation | 1.00 (0.77; 1.31) | 1.02 (0.77; 1.34) | 0.94 (0.71; 1.24) | 0.99 (0.72; 1.28) |
Lack of pain control | 0.97 (0.72; 1.32) | 1.00 (0.74; 1.36) | 1.03 (0.76; 1.41) | 1.05 (0.76; 1.45) |